Polymeric Nanocarriers Delay the Onset of Type 1 Diabetes in Nonobese Diabetic (NOD) Mice 2365

Le résumé fourni par la source

Abstract Description Introduction Teplizumab (Anti-CD3) is the first FDA-approved therapy to delay the onset of type 1 diabetes (T1D) and prolong insulin independence. However, this therapy comes with a high price tag and immunosuppressive adverse effects. We have previously demonstrated that rapamycin-loaded polymersome nanoparticles (rPS) induce immune antigen-specific tolerance towards transplanted fully-MHC mismatched islets via a costimulation blockade. To assess if this strategy can protect native islets and tolerize autoantigens, rPS was benchmarked against Anti-CD3 in a spontaneous T1D mouse model. Materials and Methods rPS was fabricated with the block copolymer poly(ethylene) glycol and polypropylene sulfide as previously described. At either 8 or 12 weeks old, female NOD mice received subcutaneous rPS injections or intravenous Anti-CD3 infusions. Results rPS protected beta cell activity and delayed the onset of T1D by 9 and 6 weeks relative to the untreated and Anti-CD3 groups, respectively. Anti-CD3-treated mice developed lymphopenia (100%) and leukopenia (37.5%) during treatment. Overall, rPS therapy showed superiority in T1D onset delay and side effect profile relative to Anti-CD3 treatment. Conclusion rPS is a promising early-intervention therapy to delay the onset of T1D. Our prior work demonstrates that rPS leverages antigen presenting cells to reprogram T cells for antigen-specific islet tolerance and can mitigate adverse events of chronic, nonspecific immunosuppression. Topic Categories Therapeutic Approaches to Autoimmunity (THER)

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.